相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors
Lucia Regales et al.
PLOS ONE (2007)
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation
Nadia Godin-Heymann et al.
CANCER RESEARCH (2007)
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy
Danan Li et al.
CANCER CELL (2007)
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
Yuki Yuza et al.
CANCER BIOLOGY & THERAPY (2007)
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity
Cai-Hong Yun et al.
CANCER CELL (2007)
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Lecia V. Sequist
ONCOLOGIST (2007)
A common signaling cascade may underlie addiction to the Src, BCR-ABL, and EGF receptor oncogenes
Sreenath V. Sharma et al.
CANCER CELL (2006)
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
Marissa N. Balak et al.
CLINICAL CANCER RESEARCH (2006)
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib
Takayuki Kosaka et al.
CLINICAL CANCER RESEARCH (2006)
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib
Kendall D. Carey et al.
CANCER RESEARCH (2006)
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas
Eunice L. Kwak et al.
CLINICAL CANCER RESEARCH (2006)
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Xuewu Zhang et al.
CELL (2006)
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
H Shigematsu et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Mutations of the epidermal growth factor receptor in non-small cell lung cancer - Search and destroy
SK Chan et al.
EUROPEAN JOURNAL OF CANCER (2006)
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
DW Bell et al.
NATURE GENETICS (2005)
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
H Greulich et al.
PLOS MEDICINE (2005)
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
TA Carter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
EL Kwak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity
HR Tsou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Mutations and addiction to EGFR:: the Achilles 'heal' of lung cancers?
AF Gazdar et al.
TRENDS IN MOLECULAR MEDICINE (2004)
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
ER Wood et al.
CANCER RESEARCH (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
PRODRG:: a tool for high-throughput crystallography of protein-ligand complexes
AW Schüttelkopf et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
Coot:: model-building tools for molecular graphics
P Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
J Stamos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to ST157, and they can pre-exist to the onset of treatment
C Roche-Lestienne et al.
BLOOD (2002)
Pushing the boundaries of molecular replacement with maximum likelihood
RJ Read
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2001)
分享论文
